- Home
- DRUG vs LUNG Comparison
DRUG vs LUNG Comparison
Compare DRUG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- LUNG
- Stock Information
- Founded
- DRUG 2019
- LUNG 1995
- Country
- DRUG United States
- LUNG United States
- Employees
- DRUG N/A
- LUNG N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- LUNG Industrial Specialties
- Sector
- DRUG Health Care
- LUNG Health Care
- Exchange
- DRUG Nasdaq
- LUNG Nasdaq
- Market Cap
- DRUG 253.2M
- LUNG 296.1M
- IPO Year
- DRUG N/A
- LUNG 2020
- Fundamental
- Price
- DRUG $36.06
- LUNG $7.05
- Analyst Decision
- DRUG Strong Buy
- LUNG Strong Buy
- Analyst Count
- DRUG 4
- LUNG 7
- Target Price
- DRUG $84.33
- LUNG $12.64
- AVG Volume (30 Days)
- DRUG 50.7K
- LUNG 485.1K
- Earning Date
- DRUG 02-14-2025
- LUNG 04-30-2025
- Dividend Yield
- DRUG N/A
- LUNG N/A
- EPS Growth
- DRUG N/A
- LUNG N/A
- EPS
- DRUG N/A
- LUNG N/A
- Revenue
- DRUG N/A
- LUNG $83,789,000.00
- Revenue This Year
- DRUG N/A
- LUNG $17.96
- Revenue Next Year
- DRUG N/A
- LUNG $18.35
- P/E Ratio
- DRUG N/A
- LUNG N/A
- Revenue Growth
- DRUG N/A
- LUNG 22.01
- 52 Week Low
- DRUG $0.93
- LUNG $5.46
- 52 Week High
- DRUG $79.02
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- DRUG 49.87
- LUNG 43.92
- Support Level
- DRUG $31.55
- LUNG $7.00
- Resistance Level
- DRUG $36.25
- LUNG $7.65
- Average True Range (ATR)
- DRUG 2.74
- LUNG 0.68
- MACD
- DRUG 0.01
- LUNG -0.21
- Stochastic Oscillator
- DRUG 66.15
- LUNG 3.40
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.